SCHEMBL4424864

SCHEMBL4424864

CC(=O)OCc1oc(-c2nn(Cc3ccccc3)c3ccccc23)nc1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2RL3 Q96RI0 1/20 0.52
PDE5A O76074 6/20 0.50
CYP2D6 P10635 8/20 0.47
CYP1A2 P05177 6/20 0.47
CYP3A4 P08684 2/20 0.47
SCN8A Q9UQD0 1/20 0.47
HPGD P15428 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 2/20 0.46
LMNA P02545 2/20 0.46
NPC1 O15118 1/20 0.46
GMNN O75496 1/20 0.46
TP53 P04637 1/20 0.46
MAPT P10636 1/20 0.46
CYP2C9 P11712 1/20 0.46
ALOX15 P16050 1/20 0.46
NFKB1 P19838 1/20 0.46
MAPK1 P28482 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4428683 0.86 PDE5A (0.61) F2RL3PDE5ACYP2D6CYP1A2CYP3A4
SCHEMBL13865173 0.85 PDE5A (0.53) F2RL3PDE5ACYP2D6CYP1A2CYP3A4
SCHEMBL4429083 0.84 PDE5A (0.58) F2RL3PDE5ACYP2D6CYP1A2CYP3A4
SCHEMBL13865176 0.79 PDE5A (0.62) F2RL3PDE5ACYP2D6CYP1A2CYP3A4
SCHEMBL3071011 0.78 PDE5A (0.74) F2RL3PDE5ACYP2D6CYP1A2CYP3A4
SCHEMBL4425538 0.74 PPARD (0.53) HPGDALDH1A1KDM4EHSD17B10TSHR
SCHEMBL5430238 0.73 F2RL3 (0.64) F2RL3PDE5ACYP2D6CYP1A2CYP3A4
SCHEMBL4434101 0.73 BUB1 (0.45) PDE5A
SCHEMBL13865175 0.73 F2RL3 (0.63) F2RL3PDE5ACYP2D6CYP1A2CYP3A4
SCHEMBL4429880 0.71 F2RL3 (0.56) F2RL3PDE5ACYP2D6CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0934311-B1 NEW HETEROCYCLYLMETHYL-SUBSTITUTED PYRAZOL DERIVATES BAYER HEALTHCARE AG (DE) 2009-05-13 EP disclosed
EP-0934311-B1 NEW HETEROCYCLYLMETHYL-SUBSTITUTED PYRAZOL DERIVATES BAYER HEALTHCARE AG (DE) 2009-05-13 EP disclosed
WO-2007065010-A2 ANTI-ANGIOGENESIS COMPOUNDS HIF BIO, INC. (US) 2007-06-07 WO disclosed
EP-1686127-A1 New heterocyclylmethyl-substituted pyrazole derivatives and their use for treating cardiovascular diseases Bayer HealthCare AG (DE) 2006-08-02 EP disclosed
US-6462068-B1 CARDIOVASCULAR DISEASES BAYER AKTIENGESELLSCHAFT (DE) 2002-10-08 US disclosed
US-6414009-B1 CARDIOVASCULAR DISORDERS; ANTICOAGULANTS BAYER AKTIENGESELLSCHAFT (DE) 2002-07-02 US disclosed
US-6410740-B1 CYCLIZATION OF THE CORRESPONDING AMIDE BAYER AKTIENGESELLSCHAFT (DE) 2002-06-25 US disclosed
US-6387940-B1 CARDIOVASCULAR DISORDERS BAYER AKTIENGESELLSCHAFT (DE) 2002-05-14 US disclosed
US-6166027-A Heterocyclylmethyl-substituted pyrazole derivatives and their use for treating cardiovascular diseases BAYER AKTIENGESELLSCHAFT (DE) 2000-12-26 US disclosed
CN-1241188-A Heterocyclylmethyl-substed pyrazol derivs. BAYER AG (DE) 2000-01-12 CN disclosed
EP-0934311-A2 NEW HETEROCYCLYLMETHYL-SUBSTITUTED PYRAZOL DERIVATES BAYER AG (DE) 1999-08-11 EP disclosed
WO-1998016507-A2 NEW HETEROCYCLYLMETHYL-SUBSTITUTED PYRAZOL DERIVATES AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES BAYER AKTIENGESELLSCHAFT (DE) 1998-04-23 WO disclosed